Skip to content
Screener

Anika Therapeutics ANIK Q1 2026 earnings

Reported April 29, 2026 · Before market open

Revenue$29.6MBeat by $1.5M
EPS$0.27Beat by $0.34
Revenue estimate$28.1M
EPS estimate-$0.07

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$29.7M
EPS estimate$0.17

Financials

Q1 2026

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$194.31M-8.8%
Enterprise value$179.03M-3.3%
P/S1.7×-0.3×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Segments

By geography

See full
Europe$6.7M+15.0%
Other Location$4.4M+10.2%

By product

See full
OEM Channel$17.0M+14.3%
Commercial Channel$12.6M+11.7%

FAQ

When did Anika Therapeutics report Q1 2026 earnings?
Anika Therapeutics (ANIK) reported Q1 2026 earnings on April 29, 2026 before market open.
What were Anika Therapeutics's Q1 2026 revenue and EPS?
Anika Therapeutics reported revenue of $29.6M and eps of $0.27 for Q1 2026.
Did Anika Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $28.1M by $1.5M. EPS beat the consensus estimate of $-0.07 by $0.34.
How did Anika Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.2% from $26.2M a year earlier.
Where can I find Anika Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-002799) and the 10-Q periodic report (0001171843-26-002852) directly on SEC EDGAR. The filing index links above go to sec.gov.